Royal London Asset Management
EPZM

Royal London Asset Management’s Epizyme, Inc EPZM Stock Holding History

Royal London Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,000
Closed -$303K – 525
2014
Q3 		$303K Hold
11,000
– – 0.01% 517
2014
Q2 		$354K Hold
11,000
– – 0.01% 574
2014
Q1 		$248K Buy
+11,000
New +$333K 0.01% 578

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Royal London Asset Management's EPZM Position: Q4 2014 in Review

Royal London Asset Management sold out of Epizyme, Inc (EPZM) in Q4 2014, closing a stake of 11,000 shares — an estimated $303K sold.

Royal London Asset Management first reported a position in EPZM in Q1 2014 and held it in 3 quarters. The position peaked at $354K in Q2 2014. 82 funds tracked by Wall St. Rank hold EPZM as of Q4 2014.

  • Royal London Asset Management reported no remaining Epizyme, Inc position as of Q4 2014 after selling out during the quarter.
  • Royal London Asset Management sold 11,000 Epizyme, Inc shares in Q4 2014, an estimated $303K.
  • Royal London Asset Management first reported a position in Epizyme, Inc in Q1 2014 and held it in 3 quarters.
  • Royal London Asset Management's Epizyme, Inc position peaked at $354K in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2014.

Based on Royal London Asset Management's 13F filing for Q4 2014, filed 11 Feb 2015.